Josh LaRosa Quoted in Bloomberg’s “Trump Hospital Price Policy May Face Obstacle in 2015 FTC Warning”
“Obviously judges might differ, but it’s not necessarily really that unreasonable to conclude HHS would have that authority,” said Josh LaRosa, a policy associate at Wynne Health Group, a health policy, public interest consulting firm that focuses on health policy.
“The jump to me doesn’t seem that wide,” he said.
As for the FTC’s comments on the Minnesota law, LaRosa doesn’t think they will be the “nail in the coffin for challenging the legality of what HHS can do,” though he does think “there is probably some truth to the concern the FTC communicates.”
The full article can be accessed here.